Despite its first-ever FDA approval, Celcuity's stock plummet shows that investors are unfazed by regulatory wins alone. In a market saturated with biotech contenders, it's becoming increasingly clear that what's needed is not just FDA approval, but a game-changing innovation that can truly disrupt the industry.